Navigation Links
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Date:2/24/2013

antihistamine. For the primary endpoint, the omalizumab 75 mg dose group did not demonstrate statistical significance compared to placebo. However, omalizumab 150 mg and 300 mg dose groups met the pre-specified primary endpoint and all eight pre-specified secondary endpoints in the ASTERIA II trial, except for the 150 mg dose that did not show a significant difference from placebo in the proportion of angioedema-free days from Week 4 to Week 12 of therapy. Patient response, as measured by the median time to Minimally Important Difference (MID) in itch severity score,  a secondary endpoint, occurred at Week 1 (300 mg dose) and Week 2 (150 mg dose), compared to Week 4 in the placebo group.

The incidence and severity of adverse events (AEs) was similar across treatment groups. The most frequently reported treatment-emergent adverse events in patients taking omalizumab (>10% in any omalizumab treatment arm) in the study (including treatment period and follow-up period) were nasopharyngitis (nasal and throat infection or common cold), idiopathic urticaria (hives and itching, trigger unknown) and headache.  Five (6.3%) patients experienced serious adverse events (SAEs) in the omalizumab 300 mg dose group, compared to two (2.5%) in the placebo group. In the 150 mg and 75 mg dose groups, one patient experienced SAEs in each group (1.1% and 1.3%, respectively). No deaths were reported during this study.

About Omalizumab
Omalizumab is not indicated for CIU.

Omalizumab is a biologic therapy unique in targeting immunoglobulin E (IgE). Research is ongoing to understand the mechanism of action of omalizumab in CIU and to investigate its potential impact on the drivers of CIU. Omalizumab is approved for the treatment of moderate to severe allergic asthma under the brand-name Xolair® in more than 90 countries, including the US since 2003 and the EU since 2005. In the US, Xolair is indicated for appropriate people who are
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
2. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
3. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
4. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
5. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
6. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
7. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
8. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
9. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
10. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21. Mai 2013 Der Vorstand ... Firmen OMNIlife science® Inc., Enztec Ltd. und Praxim ... neue, erfahrene Mitglieder in die Führungsriege gewählt. ... erfahrene Führungspersönlichkeit aus der Orthopädie, wird die ... Johnson , anerkannter Experte für medizinische ...
(Date:5/21/2013)... 2013  LCA-Vision Inc. (NASDAQ: LCAV ), a ... Plus ® brand, announces that all nominees to the company,s ... annual meeting of stockholders.  These Directors are: , ... Bahl & Gaynor Investment Counsel , John ... Edgar F. Heizer III , Chairman of ...
(Date:5/21/2013)... Mass. , May 21, 2013 /PRNewswire/ ... research and advisory firms for pharmaceutical and ... an emerging agent on key efficacy endpoints, ... progression, has the most influence over surveyed ... advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast cancer. ...
Breaking Medicine Technology:Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
... May 23, 2011 Reportlinker.com announces that ... in its catalogue: Advanced ... http://www.reportlinker.com/p0507254/Advanced-Digital-Medical-Equipment-Products-Market .html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ... sizes the advanced medical device markets, particularly ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... of Water and Wastewater Management in ... http://www.reportlinker.com/p0506839/Global-Water-Market-Outlook-Strategic-Analysis-of-Water-and-Wastewater-Management-in-the-Pharmaceutical-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Water_dis This ...
Cached Medicine Technology:Reportlinker Adds Advanced Digital Medical Equipment Products Market 2Reportlinker Adds Advanced Digital Medical Equipment Products Market 3Reportlinker Adds Advanced Digital Medical Equipment Products Market 4Reportlinker Adds Advanced Digital Medical Equipment Products Market 5Reportlinker Adds Advanced Digital Medical Equipment Products Market 6Reportlinker Adds Advanced Digital Medical Equipment Products Market 7Reportlinker Adds Advanced Digital Medical Equipment Products Market 8Reportlinker Adds Advanced Digital Medical Equipment Products Market 9Reportlinker Adds Advanced Digital Medical Equipment Products Market 10Reportlinker Adds Advanced Digital Medical Equipment Products Market 11Reportlinker Adds Advanced Digital Medical Equipment Products Market 12Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 2Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 3Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 4
(Date:5/21/2013)... 2013, Paris, France: One-year results from SOURCE XT ... (TAVI) registries to-date reported today at EuroPCR 2013 ... high rates of device success for all access approaches, ... Post-Approval Study followed up 2688 consecutively enrolled patients (mean ... heart valve at 93 centres in 17 countries between ...
(Date:5/21/2013)... May 21, 2013 According to a May ... the Use of Botox,” Botox injections have become ... approval in 2002 (Go to goo.gl/8iYbD). Although it is mostly ... with men. The injection makes facial wrinkles less visible by ... last for about three months. This means that people who ...
(Date:5/21/2013)... May 21, 2013 Phoseon Technology will ... at the 20th Annual IMI European Ink Jet Conference ... market leader, Phoseon continues to invest in product development ... adoption of UV LED curing in printing applications. ... on the market offering both air cooled and water ...
(Date:5/21/2013)... MedMar Healing Center announces their participation in the ... Twenty-eight businesses, including MedMar Healing Center, doctors, and clubs, are ... is to raise food to help area kids who have ... recent years. , “We like being able to give ... Douglas Chloupek of MedMar Healing Center. “Taking part in the ...
(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3
... problems faced by youngsters with the disease , THURSDAY, July ... more likely to be overweight than those without the disease, ... The finding is from a major study that explored the ... a less common form of the disease that usually shows ...
... the launch of (RED)ZONES at the first U2 360 Degrees concert ... rapturous sold out crowd of 90,000 fans. , , ... will be present throughout the U2 tour. The tickets for ... the ticket sales going to the Global Fund to help fund ...
... 2 "If recent reports of DEA intervention are accurate, ... Diversion unit, and it won,t end there. The pharmacists who ... as will everyone whose name is associated with any of ... , Mr. Mullin won full federal jury acquittal at ...
... DUBLIN, Ohio, July 2 Cardinal Health today announced that ... effective upon the completion of the planned spinoff of CareFusion ... board for personal reasons after 22 years of service to ... Downey is the former chairman and chief executive officer of ...
... committee,s recommendations to the U.S. Food and Drug Administration (FDA) to put ... from the American Academy of Pain Medicine (AAPM), ... The American Academy of Pain Medicine (AAPM), which ... Pain Medicine, supports the safe and responsible, ...
... plug a Percocet-Vicodin gap, experts say, , THURSDAY, July 2 ... which a U.S. health advisory panel has urged, would not ... , The reason, they say, is that other options are ... made its recommendation Tuesday. It followed the release in May ...
Cached Medicine News:Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3Health News:DEA Will Play Hardball in Investigating Michael Jackson's Doctors 2Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 2Health News:If 2 Painkillers Are Banned, What Next? 2Health News:If 2 Painkillers Are Banned, What Next? 3Health News:If 2 Painkillers Are Banned, What Next? 4
... excellent choice for orthopedic procedures. ... to 24" for the surgeon's ... quickly attach to any O.R. table. ... C-Arm access and stability. Optional ...
... and ultra versatile model angulates for ... adjust the height of the support ... single post, or double tee foot. ... physician comfort and stability. A convenient ...
... torso and leg sections of ... simultaneously lift body and legs. ... raises and lowers legs individually ... A wide range of adjustment ...
... The PROfx elevates the surgical table to ... by providing the perfect table complement for ... an integral role in the surgical process, ... skill of the surgeon to minimize the ...
Medicine Products: